| 1 |
�~ˆ³–ò‚Ì�Å�VƒGƒrƒfƒ“ƒX�@’†–ì‘å‰î�A�¼ŽR�@�¬�@CURRENT THERAPY, 36�i1�j: 83-88, 2018 |
| 2 |
�t‘ŸŠw�@‚±‚̈ê”N‚Ì�i•à�@�t‚Æ�‚ŒŒˆ³�@–k“cŒ¤�l�A’†–ì‘å‰î�A�lŒ©�_Žj�A�¼ŽR�@�¬�@“ú–{�t‘ŸŠw‰ïŽ�, 60(1): 36-40, 2018 |
| 3 |
SGLT2‘jŠQ–ò‚ÆŒŒˆ³“ú“à•Ï“®�@�lŒ©�_Žj�A�¼ŽR�@�¬�@ŒŒˆ³, 25(4): 226-227, 2018 |
| 4 |
�t�E”å”AŠíŒn-‹}�«�E–��«�t•s‘S‚Ì–ò•¨Ž¡—Ã�@�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP277-283�A2018 |
| 5 |
�t�E”å”AŠíŒn-Œ´”�«Ž…‹…‘ÌŽ¾Š³‚Ì–ò•¨Ž¡—Ã�@ŽRú±‘å•ã�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP284-300�A2018 |
| 6 |
�t�E”å”AŠíŒn-�tŒŒŠÇ�«�‚ŒŒˆ³‚Ì–ò•¨Ž¡—Ã�@’†–ì‘å‰î�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP301-304�A2018 |
| 7 |
�t�E”å”AŠíŒn-�tá±�t‰Š‚Ì–ò•¨Ž¡—Ã�@’†–ì‘å‰î�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP305-310�A2018 |
| 8 |
�t�E”å”AŠíŒn-‹}�«�E–��«”A�׊NJԎ¿�«�t‰Š‚Ì–ò•¨Ž¡—Ã�@’†–ì‘å‰î�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP311-314�A2018 |
| 9 |
�t�E”å”AŠíŒn-“ñŽŸ�«Ž…‹…‘ÌŽ¾Š³‚Ì–ò•¨Ž¡—Ã�@ŽRú±‘å•ã�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP315-325�A2018 |
| 10 |
�t�E”å”AŠíŒn-�í�õ�F‘Ì—D�«ˆâ“`‘½”�«”X–E�t‚Ì–ò•¨Ž¡—Ã�@ŽRú±‘å•ã�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP326-328�A2018 |
| 11 |
�_Œo�E�¸�_Œn-�œŠi‹Ø’oŠÉ–ò�@–k‘º—T—º�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP389-395�A2018 |
| 12 |
�_Œo�E�¸�_Œn-–ƒ�Œ–ò�@–k‘º—T—º�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP396-406�A2018 |
| 13 |
Š´�õ�Ç-Š´�õ�ÇŽ¡—Öò�@�¬�â�M“ñ�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP439-445�A2018 |
| 14 |
Š´�õ�Ç-ƒEƒBƒ‹ƒXŠ´�õ�ǂ̎¡—Öò�@�¬�â�M“ñ�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP446-456�A2018 |
| 15 |
Š´�õ�Ç-�׋ۊ´�õ�ǂ̎¡—Öò�@�¬�â�M“ñ�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP457-476�A2018 |
| 16 |
Š´�õ�Ç-�^‹ÛŠ´�õ�Ç�AŠñ�¶’Ž�ǂ̎¡—Öò�@�¬�â�M“ñ�A�¼ŽR�@�¬�@�V‚µ‚¢–ò—�Šw : �¼‘º�‘“X�A�Έä–M–¾�A�¼ŽR�@�¬ŠÄ�C�AP477-484�A2018 |
| 17 |
”sŒŒ�Ç�«�t�áŠQ‚ɑ΂·‚éANP‚ÌŒø‰Ê�@–k‘º—T—º�A’†–ì‘å‰î�A�¼ŽR�@�¬�@ŒŒŠÇ: 41(4): 1-8, 2018 |
18 |
”ñƒXƒeƒ�ƒCƒh�«�V‹KMRƒuƒ�ƒbƒJ�[ƒGƒTƒLƒZƒŒƒmƒ“�iCS-3150)‚Ì–ò—�Šw“I“Á�«‚ÆŠî‘bƒGƒrƒfƒ“ƒX�@�XàV‹I•F�A�¼ŽR�@�¬�@ŒŒˆ³, 25�i5�j: 377-381, 2018 |
| 19 |
SGLT2‘jŠQ–ò‚É‚æ‚é‰Â”\�«‚ð’T‚é-‚Í‚¶‚ß‚É-�@�¼ŽR�@�¬�@ˆãŠw‚Ì‚ ‚ä‚Ý, 266(4): 255, 2018 |
| 20 |
�V‹K�~ˆ³–ò‚ÌŠJ”“®Œü�@�¼ŽR�@�¬�@“ú–{—Õà¬, 76(8): 1461-1467 2018 |
| 21 |
���ì‘åŠwˆãŠw•”�Љî�y–ò—�Šw�z�@�¼ŽR�@�¬�@���쌧ˆãŽt‰ïŽ�,: 71(4): 23-25 2018 |
| 22 |
ˆÙ•ª–ì‚©‚ç�s‚«’…‚¢‚½‚ª‚ñŒ¤‹†�u�iƒvƒ��jƒŒƒjƒ“Žó—e‘Ì�v�@�¼ŽR�@�¬�@“ú–{‚ª‚ñ—\–hŠw‰ïNEWSLETTER,: 97�F5-6 2018 |
| 23 |
�H‰–Š´Žó�«�‚ŒŒˆ³ƒ‰ƒbƒg‚É‚¨‚¢‚Ä�¶‚¶‚½�t‘g�D�áŠQ‚Í�AŒ¸‰–‚Æ‚`‚q‚a�E‚b‚b‚a‚É‚æ‚錵–§‚È�~ˆ³‚É‚æ‚èŒã‘Þ‚µ‚¤‚é�@�¼ŽR�@�¬�AKazi R�A�X�ì�@‹M�AŽÄ“cвŽq�AŠÝ“c�^Žk�Aà_“c�^�G�A–k—Ñ�ç’ÃŽq�A�¬�¼Œ[•v�A�¡�¼��m�@�t‚ƃtƒŠ�[ƒ‰ƒWƒJƒ‹, 13�F78-79 2018 |
| 24 |
�t‘Ÿ•a‚ÆRAAŒn‘jŠQ–ò‚Ìupdate�@�¼ŽR�@�¬�@�t‘Ÿ“à‰È�E”å”AŠí‰È: 8(2): 115-119, 2018 |
| 25 |
ƒ}ƒEƒX‚Ì�t‹•ŒŒ/�ÄŸó—¬��ŠQŒã‚ÌSGLT2‘jŠQ–ò�ˆ—�‚Í�t‘Ÿ‚Ì–Ñ�׌ŒŠÇ‘¹��‚Æ�üˆÛ‰»‚ð—}�§‚·‚é(Treatment with the SGLT2 inhibitor luseogliflozin attenuated renal capillary injury and fibrosis after renal ischemia/reperfusion injury in mice) �@�¼ŽR �¬, �lŒ© �_Žj, ’†–ì ‘å‰î�@“ú–{“à•ª”åŠw‰ïŽGŽ� 94(4) 1601 - 1601, 2018 |
| 26 |
ƒ‰ƒbƒg‚É‚¨‚¢‚Ä�‚�H‰–“Š—^‚Í�tŒðŠ´�_ŒoŠˆ�«‚ð—}�§‚µŠÌ‘Ÿ‚ł̔A‘fŽY�¶‚ð˜´�i‚·‚é �@�XàV ‹I•F, –k“c Œ¤�l, ŽR�è ‘å•ã, ’†–ì ‘å‰î, “¡àV —ljp, �lŒ© �_Žj, ƒCƒFƒ“ƒX�EƒeƒBƒbƒ`ƒF, �¼ŽR �¬�@“ú–{�‚ŒŒˆ³Šw‰ï‘�‰ïƒvƒ�ƒOƒ‰ƒ€�E�´˜^�W 41‰ñ OB06 - 03, 2018 |
| 27 |
Šî‘b‚©‚ç‚Ý‚½�t‘ŸŒ¤‹†‚Ì�Å‘O�ü �@�¼ŽR�@�¬�@“ú–{—Õ�°–ƒ�ŒŠw‰ïŽ� 38(3) 315 - 321, 2018 |
| 28 |
�t‹•ŒŒ�ÄŸó—¬��ŠQŒã‚̃}ƒEƒX‚É‚¨‚¢‚ÄSGLT2‘jŠQ•¨Ž¿luseogliflozin“Š—^‚Í�t–Ñ�׌ŒŠÇ‘¹��‚Æ�üˆÛ‰»‚ð—}�§‚µ‚½(Treatment with the SGLT2 inhibitor luseogliflozin attenuated renal capillary injury and fibrosis after renal ischemia/reperfusion injury in mice) �@�¼ŽR �¬, �lŒ© �_Žj, ’†–ì ‘å‰î�@“ú–{“à•ª”åŠw‰ïŽGŽ� 94(1) 431 - 431, 2018 |
| 29 |
’´‰¹”gƒAƒVƒXƒg’†�ÔŠO•ªŒõ–@‚ð—p‚¢‚½�¶‘Ì“àŠO‚É‚¨‚¯‚錌“œ’lƒ‚ƒjƒ^ƒŠƒ“ƒO : “§�Í‘•’u‚Ö‚Ì“‹�Ú‚ð–ÚŽw‚µ‚½’´‰¹”g‰t‘̃Zƒ‹ƒ†ƒjƒbƒg‚Ì’ñˆÄ (Œõ�E—ÊŽqƒfƒoƒCƒXŒ¤‹†‰ï�EƒoƒCƒIƒ�ƒfƒBƒJƒ‹ƒtƒHƒgƒjƒNƒX‰ž—p) �@”T‘º �G�K, �쓈 ‚Ȃ‚Ý, –k�è —F�Æ, �X Œh‘¾, �N àjŒŽ, �¼ŽR �¬, ˜a“c Œ’Ži, �ÎŠÛ ˆÉ’m˜Y�@“d‹CŠw‰ïŒ¤‹†‰ïŽ‘—¿. OQD = The papers of technical meeting on optical and quantum devices, IEE Japan 2018(1) 11 - 14, 2018 |
| 30 |
’´‰¹”gƒAƒVƒXƒg’†�ÔŠO•ªŒõƒCƒ��[ƒWƒ“ƒO‚ð—p‚¢‚½�¶‘Ì“àŠO‚É‚¨‚¯‚錌“œ’lƒ‚ƒjƒ^ƒŠƒ“ƒO : ƒTƒ“ƒvƒ‹•\‘w‹ß–T‚©‚ç‚̃pƒ‰ƒ�ƒgƒŠƒbƒN’è�Ý”g‚ð—p‚¢‚½“à•””½ŽËŒõŒŸ�o (Œõ�E—ÊŽqƒfƒoƒCƒXŒ¤‹†‰ï�EƒoƒCƒIƒ�ƒfƒBƒJƒ‹ƒtƒHƒgƒjƒNƒX‰ž—p) �@–k�è —F�Æ, �쓈 ‚Ȃ‚Ý, ”T‘º �G�K, �N àjŒŽ, �¼ŽR �¬, ˜a“c Œ’Ži, �ÎŠÛ ˆÉ’m˜Y�@“d‹CŠw‰ïŒ¤‹†‰ïŽ‘—¿. OQD = The papers of technical meeting on optical and quantum devices, IEE Japan 2018(1) 15 - 19 , 2018 |
| 31 |
’´‰¹”gƒAƒVƒXƒg’†�ÔŠO•ªŒõƒCƒ��[ƒWƒ“ƒO‚ð—p‚¢‚½�¶‘Ì“àŠO‚É‚¨‚¯‚錌“œ’lƒ‚ƒjƒ^ƒŠƒ“ƒO : ”ñ�N�PŒŒ“œ’lƒZƒ“ƒT�[‚ÌŒv‘ª—̈æ‘I’è‚ð–Ú“I‚Æ‚µ‚½ƒ}ƒEƒXލ“à•”‚̃Oƒ‹ƒR�[ƒXŒŸ�o (Œõ�E—ÊŽqƒfƒoƒCƒXŒ¤‹†‰ï�EƒoƒCƒIƒ�ƒfƒBƒJƒ‹ƒtƒHƒgƒjƒNƒX‰ž—p) �@�쓈 ‚Ȃ‚Ý, –k�è —F�Æ, ”T‘º �G�K, �N àjŒŽ, �¼ŽR �¬, ˜a“c Œ’Ži, �ÎŠÛ ˆÉ’m˜Y�@“d‹CŠw‰ïŒ¤‹†‰ïŽ‘—¿. OQD = The papers of technical meeting on optical and quantum devices, IEE Japan 2018(1) 7 - 10, 2018 |
| 32 |
”ñ�N�PŒŒ“œ’lƒZƒ“ƒT�[‚ð–ÚŽw‚µ‚½ƒpƒ‰ƒ�ƒgƒŠƒbƒN’è�Ý”g‚É‚æ‚é�¶‘Ì–Œ“à•”‚É‚¨‚¯‚锽ŽË–Ê�¶�¬Žè–@ �@�N àjŒŽ, –k�è —F�Æ, �쓈 ‚Ȃ‚Ý, �¼ŽR �¬, ˜a“c Œ’Ži, �ÎŠÛ ˆÉ’m˜Y�@�¸–§�HŠw‰ïŠw�p�u‰‰‰ï�u‰‰˜_•¶�W 2018 815 - 816, 2018 |
| 33 |
’´‰¹”gƒAƒVƒXƒg’†�ÔŠO•ªŒõ–@‚É‚æ‚é“§�ÍŽž‚ÌŒŒ“œ’lƒ‚ƒjƒ^ƒŠƒ“ƒO‚ð–Ú“I‚Æ‚µ‚½‰t‘̃Zƒ‹‚Ì’ñˆÄ �@”T‘º �G�K, �X Œh‘¾, �쓈 ‚Ȃ‚Ý, –k�è —F�Æ, �¼ŽR �¬, ˜a“c Œ’Ži, �ÎŠÛ ˆÉ’m˜Y�@�¸–§�HŠw‰ïŠw�p�u‰‰‰ï�u‰‰˜_•¶�W 2018 813 - 814 2018 |
| 34 |
’†�ÔŠO•ªŒõ–@‚É‚æ‚éƒXƒ}�[ƒgƒgƒCƒŒ‚ÌŽÀŒ»‚ð–ÚŽw‚µ‚½’´‰¹”g‰t‘̃Zƒ‹‚Ì’ñˆÄ �@”ö”¨ �Ž�Æ, �ÎŠÛ ˆÉ’m˜Y, ˆäŒ´ �‹‘¾, �X Œh‘¾, ŽR–{ ’¼�K, �쓈 ‚Ȃ‚Ý, ‰¤ ˜¸““, –k�è —F�Æ, �¼ŽR �¬, ˜a“c Œ’Ži�@�¸–§�HŠw‰ïŠw�p�u‰‰‰ï�u‰‰˜_•¶�W 2018 825 - 826, 2018 |
| 35 |
“¤—±‘å’†�ÔŠO•ªŒõƒ†ƒjƒbƒg‚É‚æ‚é“§�Í‘•’u‚Ìin-situŒŒ“œ’lƒ‚ƒjƒ^ƒŠƒ“ƒO �@”T‘º �G�K, –싽 �F‰î, �쓈 ‚Ȃ‚Ý, –k�è —F�Æ, �N àjŒŽ, �¼ŽR �¬, �ÎŠÛ ˆÉ’m˜Y�@�¸–§�HŠw‰ïŠw�p�u‰‰‰ï�u‰‰˜_•¶�W 2018 529 - 530, 2018 |